Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMXIN002 vs EpiPen PK/PD in Allergic Rhinitis
NCT07228325Phase 2Enrolling by invitation
- Sponsor
- Nasus Pharma
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FMXIN002 in anaphylaxis, sponsored by Nasus Pharma. Started Nov 2025; status: enrolling by invitation.
02
Drugs
FMXIN002
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT07228325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228325.